11 results match your criteria: "Atlanta (W.J.C.); and the University of Maryland[Affiliation]"
Concurrently Low Coronary Flow Reserve and Low Index of Microvascular Resistance Are Associated With Elevated Resting Coronary Flow in Patients With Chest Pain and Nonobstructive Coronary Arteries.
Circ Cardiovasc Interv
March 2022
Division of Cardiology, Southlake Regional Health Centre, Newmarket, Ontario, Canada (M.M., W.J.C., S.E.S.M.).
Background: Coronary microvascular function can be distinctly quantified using the coronary flow reserve (CFR) and index of microvascular resistance (IMR). Patients with low CFR can present with low or high IMR, although the prevalence and clinical characteristics of these patient groups remain unclear.
Methods: One hundred ninety-nine patients underwent coronary microvascular assessments using coronary thermodilution techniques.
Vestibular Rehabilitation for Peripheral Vestibular Hypofunction: An Updated Clinical Practice Guideline From the Academy of Neurologic Physical Therapy of the American Physical Therapy Association.
J Neurol Phys Ther
April 2022
Hearing and Balance Research Program, James H. Quillen VAMC, Mountain Home, and Physical Therapy Program, Department of Rehabilitative Sciences, East Tennessee State University, Johnson City, Tennessee (C.D.H.); Department of Physical Medicine and Rehabilitation, School of Medicine (Emerita), Emory University, Atlanta, Georgia (S.J.H.); Department of Physical Therapy, School of Health and Rehabilitation Science, University of Pittsburgh, Pittsburgh, Pennsylvania (S.L.W., J.M.F.); Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania (S.L.W., J.M.F.); Department of Otolaryngology, University of Rochester, Rochester, New York (E.R.A.); Department of Otolaryngology, Michigan Medicine, University of Michigan, Ann Arbor (W.J.C.); Army-Baylor University Doctoral Program in Physical Therapy, Fort Sam Houston, Texas (C.W.H.); Otolaryngology, University of Colorado School of Medicine, Denver (S.P.C.); Department of Physical Therapy, The University of Alabama at Birmingham, Birmingham (J.B.C.); Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas (H.S.C.); Balance Disorders and Vestibular Neurology, Barrow Neurological Institute, Phoenix, and Department of Neurology, University of Arizona College of Medicine, Phoenix, Arizona (T.D.F.); Otorhinolaryngology, Mayo College of Medicine, Rochester, Minnesota (N.T.S.); Department of Orthopaedics, Doctor of Physical Therapy Division and Department of Head and Neck Surgery & Communication Sciences, Duke University Medical Center, Durham, North Carolina (R.A.C.); College of Chiropractic, Parker University, Dallas, Texas (J.D.D.); Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, Saint Louis, Missouri (J.A.G.); Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland (D.M.); Vestibular Disorders Association (VeDA), Portland, Oregon (C.R.); and Quillen College of Medicine Library, East Tennessee State University, Johnson City (N.J.W., R.L.W.).
Background: Uncompensated vestibular hypofunction can result in symptoms of dizziness, imbalance, and/or oscillopsia, gaze and gait instability, and impaired navigation and spatial orientation; thus, may negatively impact an individual's quality of life, ability to perform activities of daily living, drive, and work. It is estimated that one-third of adults in the United States have vestibular dysfunction and the incidence increases with age. There is strong evidence supporting vestibular physical therapy for reducing symptoms, improving gaze and postural stability, and improving function in individuals with vestibular hypofunction.
View Article and Find Full Text PDFTreatment of Vestibular Disorders (Inner Ear Balance Problems): How Does Your Physical Therapist Treat Dizziness Related to Inner Ear Balance Problems?
J Neurol Phys Ther
April 2022
Hearing and Balance Research Program (C.D.H.), Mountain Home VAMC, Mountain Home, Tennessee; Physical Therapy Program (C.D.H.), Department of Rehabilitative Sciences, East Tennessee State University, Johnson City, Tennessee; Department of Physical Medicine and Rehabilitation (S.J.H.), School of Medicine (Emerita), Emory University, Atlanta, Georgia; Department of Physical Therapy (S.L.W.), School of Health and Rehabilitation Science, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Otolaryngology (S.L.W.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Otolaryngology (E.R.A.), University of Rochester, Rochester, New York; Department of Otolaryngology (W.J.C.), Michigan Medicine, University of Michigan, Ann Arbor, Michigan; Army-Baylor University Doctoral Program in Physical Therapy (C.W.H.), Fort Sam Houston, Texas.
Dizziness is very common, but it is never normal. Dizziness can make performing daily activities, work, and walking difficult. Inner ear balance problems can make people dizzy when they turn their head, which can cause problems during walking and make people more likely to fall.
View Article and Find Full Text PDFValidation of an algorithm for identifying MS cases in administrative health claims datasets.
Neurology
March 2019
From the Department of Veterans Affairs Post Deployment Health Services (W.J.C., M.T.W.), Multiple Sclerosis Center of Excellence; University of Maryland (W.J.C.), Baltimore; Departments of Internal Medicine and Community Health Sciences (R.A.M., S.L.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; Neurology Department (A.L.-G., L.H.C.), Kaiser Permanente Southern California, Los Angeles; Georgetown University School of Medicine (M.T.W.), Washington, DC; University of Colorado (J.C.), Denver; Stanford University School of Medicine (L.M.N.), CA; McKing Consulting Corp (W.E.K., L.W.), Atlanta, GA; Faculty of Medicine (Neurology) and Centre for Brain Health (H.T.), University of British Columbia, Vancouver; College of Pharmacy and Nutrition (C.E.), University of Saskatchewan; Health Quality Council (Saskatchewan) (S.Y.), Saskatoon, Canada; and National Multiple Sclerosis Society (N.G.L.), New York, NY.
Objective: To develop a valid algorithm for identifying multiple sclerosis (MS) cases in administrative health claims (AHC) datasets.
Methods: We used 4 AHC datasets from the Veterans Administration (VA), Kaiser Permanente Southern California (KPSC), Manitoba (Canada), and Saskatchewan (Canada). In the VA, KPSC, and Manitoba, we tested the performance of candidate algorithms based on inpatient, outpatient, and disease-modifying therapy (DMT) claims compared to medical records review using sensitivity, specificity, positive and negative predictive values, and interrater reliability (Youden J statistic) both overall and stratified by sex and age.
The prevalence of MS in the United States: A population-based estimate using health claims data.
Neurology
March 2019
From the Department of Veterans Affairs Multiple Sclerosis Center of Excellence (M.T.W., W.J.C.); Georgetown University School of Medicine (M.T.W.), Washington, DC; University of Maryland (W.J.C.), Baltimore; University of Colorado (J.D.C., P.D.), Aurora; Stanford University School of Medicine (L.M.N., B.T.), CA; Southern California Permanente Medical Group (A.L.-G., L.H.C.), Pasadena; Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; University of Alabama at Birmingham (G.R.C.); McKing Consulting Corp (W.E.K., L.W.), Atlanta, GA; Faculty of Medicine (Neurology) and Centre for Brain Health (H.T.), University of British Columbia, Vancouver, Canada; Brown University (S.L.B.), Providence, RI; and National Multiple Sclerosis Society (N.G.L.), New York, NY.
Objective: To generate a national multiple sclerosis (MS) prevalence estimate for the United States by applying a validated algorithm to multiple administrative health claims (AHC) datasets.
Methods: A validated algorithm was applied to private, military, and public AHC datasets to identify adult cases of MS between 2008 and 2010. In each dataset, we determined the 3-year cumulative prevalence overall and stratified by age, sex, and census region.
A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS.
Neurology
March 2019
From the Division of Epidemiology, Department of Health Research and Policy (L.M.N.), Stanford University School of Medicine, Stanford, CA; Department of Veterans Affairs Multiple Sclerosis Center of Excellence (VA MSCoE) and Georgetown University School of Medicine (M.T.W.), Washington, DC; Department of Internal Medicine (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; VA MS Center of Excellence and University of Maryland (W.J.C.), Baltimore; Neurology Department (A.L.-G.), Kaiser Permanente Southern California, Los Angeles; University of Colorado (J.C.), Denver; Brown University (S.B.), Providence, RI; University of British Columbia (H.T.), Vancouver, Canada; University of Alabama at Birmingham (G.C.); McKing Consulting Corporation (W.K., L.W.), Atlanta, GA; and National Multiple Sclerosis Society (N.G.L.), New York, NY.
Objective: Considerable gaps exist in knowledge regarding the prevalence of neurologic diseases, such as multiple sclerosis (MS), in the United States. Therefore, the MS Prevalence Working Group sought to review and evaluate alternative methods for obtaining a scientifically valid estimate of national MS prevalence in the current health care era.
Methods: We carried out a strengths, weaknesses, opportunities, and threats (SWOT) analysis for 3 approaches to estimate MS prevalence: population-based MS registries, national probability health surveys, and analysis of administrative health claims databases.
Outcomes After Coronary Stenting or Bypass Surgery for Men and Women With Unprotected Left Main Disease: The EXCEL Trial.
JACC Cardiovasc Interv
July 2018
New York Presbyterian Hospital, Columbia University Medical Center, and the Cardiovascular Research Foundation, New York, New York.
Objectives: The aim of the present study was to assess outcomes after coronary artery bypass grafting surgery (CABG) and percutaneous coronary intervention (PCI) according to sex in a large randomized trial of patients with unprotected left main disease.
Background: In the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) trial, sex had a significant interaction effect with revascularization strategy, and women had an overall higher mortality when treated with PCI than CABG.
Methods: The EXCEL (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial was a multinational randomized trial that compared PCI with everolimus-eluting stents and CABG in patients with unprotected left main disease.
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
N Engl J Med
April 2016
From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.).
Background: Grade 2 gliomas occur most commonly in young adults and cause progressive neurologic deterioration and premature death. Early results of this trial showed that treatment with procarbazine, lomustine (also called CCNU), and vincristine after radiation therapy at the time of initial diagnosis resulted in longer progression-free survival, but not overall survival, than radiation therapy alone. We now report the long-term results.
View Article and Find Full Text PDFAdult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance).
Neurooncol Pract
December 2015
Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , 1515 Holcombe Blvd, Unit 97, Houston, TX 77030 (P.D.B.); Department of Radiation Oncology , Mayo Clinic , 200 SW 1st St, Rochester, MN 55905 (P.D.B.); Alliance Statistics and Data Center, Department of Health Sciences Research , Mayo Clinic , 200 SW 1st St, Rochester, MN 55905 (S.K.A., X.W.C); Department of Neurology , Mayo Clinic , 200 SW 1st St, Rochester, MN 55905 (B.P.O.); Division of Anatomic Pathology , Mayo Clinic , 200 SW 1st St, Rochester, MN 55905 (C.G.); Department of Medical Oncology , Mayo Clinic , 200 SW 1st St, Rochester, MN 55905 (E.G., J.C.B.); Delaware/Christiana Care CCOP , 4701 Ogletown-Stanton Rd Ste 1109, Newark, DE 19713 (S.A.S.); Department of Radiation Oncology , Rush University Medical Center , 500 S Paulina St Atrium Bldg Ground Floor, Chicago, IL 60612 (R.A.A.); Department of Radiation Oncology , Emory University School of Medicine , 1365 Clifton Rd NE Ste A-1358, Atlanta, GA 30322 (W.J.C.); Department of Radiation Oncology , Wake Forest University Medical Center, 2000 W. First St. Ste 101, Winston-Salem, NC 27104 (E.G.S.).
Background: Pilocytic astrocytoma is a rare tumor in adults. This report is of a prospective clinical trial with long-term follow-up.
Methods: Between 1986 and 1994, 20 eligible adults with supratentorial pilocytic astrocytomas were enrolled in a prospective intergroup trial of radiotherapy (RT) after biopsy (3 patients) or observation after gross (11 patients) or subtotal (6 patients) resection.
Progress in treatment by percutaneous coronary intervention: the stent of the future.
Rev Esp Cardiol (Engl Ed)
June 2013
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands. Electronic address:
First generation drug-eluting stents have considerably reduced in-stent restenosis and broadened the applications of percutaneous coronary interventions for the treatment of coronary artery disease. The polymer is an integral part of drug-eluting stents in that, it controls the release of an antiproliferative drug. The main safety concern of first generation drug-eluting stents with permanent polymers--stent thrombosis--has been caused by local hypersensitivity, delayed vessel healing, and endothelial dysfunction.
View Article and Find Full Text PDFA randomized trial of bevacizumab for newly diagnosed glioblastoma.
N Engl J Med
February 2014
From the University of Texas M.D. Anderson Cancer Center (M.R.G., T.S.A., J.S.W., P.D.B., I.W.T.-L., E.P.S., K.D.A.) and the University of Texas Health Science Center School of Nursing (T.S.A.), Houston; American College of Radiology (J.J.D., S.P., M.W.) and Thomas Jefferson University (M.W.-W.) - both in Philadelphia; the University of Chicago, Chicago (J.J.D.); Tel-Aviv Medical Center, Tel Aviv, Israel (D.T.B.); Cleveland Clinic, Cleveland (M.A.V.); the University of Utah, Salt Lake City (H.C.); Ohio State University, Columbus (A.C.); University of Wisconsin, Madison (R.J.); Mayo Clinic, Jacksonville, FL (K.A.J.); University of Virginia, Charlottesville (D.S.); Southeast Cancer Control Consortium, Winston-Salem, NC (V.W.S.); Barrow Neurologic Institute, Phoenix, AZ (D.G.B.); Emory University, Atlanta (W.J.C.); and the University of Maryland, Baltimore (M.P.M.).
Background: Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurrent glioblastoma. Whether the addition of bevacizumab would improve survival among patients with newly diagnosed glioblastoma is not known.
View Article and Find Full Text PDF